Scarica l'app Stockscreener
15.39
0.84%
-0.13
Dopo l'orario di chiusura:
15.52
0.13
+0.84%
Precedente Chiudi:
$15.52
Aprire:
$15.32
Volume 24 ore:
1.01M
Relative Volume:
1.01
Capitalizzazione di mercato:
$1.98B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-7.1402
EPS:
-2.1554
Flusso di cassa netto:
-
1 W Prestazione:
-5.81%
1M Prestazione:
+4.55%
6M Prestazione:
+26.04%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$15.03
$16.05
Intervallo di 1 settimana:
$15.03
$16.62
Portata 52W:
$11.00
$22.67
Generate Biomedicines Inc Stock (GENB) Company Profile
Nome
Generate Biomedicines Inc
Settore
Industria
Telefono
888-469-0055
Indirizzo
101 SOUTH STREET, SUITE 900, SOMERVILLE
Compare GENB vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GENB
Generate Biomedicines Inc
|
15.39 | 1.99B | 0 | 0 | 0 | -2.1554 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Generate Biomedicines Inc Stock (GENB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-13 | Iniziato | H.C. Wainwright | Buy |
| 2026-03-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2026-03-24 | Iniziato | Goldman | Buy |
| 2026-03-24 | Iniziato | Guggenheim | Buy |
| 2026-03-24 | Iniziato | Morgan Stanley | Overweight |
| 2026-03-24 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Generate Biomedicines Inc Borsa (GENB) Ultime notizie
Generate Biomedicines at Cantor healthcare conference: pipeline gains traction By Investing.com - Investing.com South Africa
Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat
H.C. Wainwright reiterates Buy on Generate Biomedicines stock By Investing.com - Investing.com Canada
Generate Biomedicines (GENB) Slips 3% as Shares Test Key Support at $15.11Imbalance Zone - dars.gov.et
Generate Biomedicines to Present at Upcoming Investor Conferences - Quiver Quantitative
Five September talks will stream online from Generate Biomedicines - Stock Titan
Generate Biomedicines (GENB) Stock Price, News & Analysis - MarketBeat
Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Layoff Tracker: TScan axes 75% of workforce, prioritizes solid tumor program - BioSpace
Director at Generate Biomedicines (GENB) sells 1,000 shares near $16 - Stock Titan
Frances Arnold plans 2026 stock sale in Generate Biomedicines (NASDAQ: GENB) - Stock Titan
Director at Generate Biomedicines (GENB) lines up a major stock sale - Stock Titan
Generate Biomedicines stock price target raised to $30 by H.C. Wainwright on asthma data - Investing.com UK
H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $30 - Moomoo
Generate Biomedicines Is Maintained at Buy by HC Wainwright & Co. - Moomoo
Companies Like Generate Biomedicines (NASDAQ:GENB) Are In A Position To Invest In Growth - simplywall.st
Nvidia GPUs Are Table Stakes in AI Drug Discovery, Generate Biomedicines CTO Says - finance.biggo.com
Generate Biomedicines Reports Premature Release of GB-0895 Clinical Posters Ahead of ERS Congress 2026 - Kalkine Media
Certain Warrants of Generate Biomedicines, Inc. are subject to a Lock-Up Agreement Ending on 26-AUG-2026. - marketscreener.com
Generate Biomedicines shares jump 20% ahead of post-IPO lock-up expiry - Pluang
Nvidia backs Generate Biomedicines in AI drug discovery push - scanx.trade
Generate Biomedicines Inc (NASDAQ:GENB) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Generate Biomedicines Inc's (NASDAQ:GENB) Lock-Up Period To End on August 26th - MarketBeat
Generate Biomedicines (NASDAQ:GENB) Shares Up 4.9%Still a Buy? - MarketBeat
8 Stocks Nvidia Has Invested InU.S. News - U.S. News - Money
Morgan Stanley Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Generate Biomedicines (GENB) Stock Trends and Sentiment 2026 - MarketBeat
Q3 EPS Estimate for Generate Biomedicines Lowered by Analyst - MarketBeat
Generate Biomedicines (NASDAQ:GENB) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Piper Sandler Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Generate Biomedicines Shares Fall Following Q2 Financial Results - marketscreener.com
Earnings Flash (GENB) Generate Biomedicines Inc. Reports Q2 Revenue $6.3M - marketscreener.com
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business ... - Caledonian Record
Press Release: Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update - Moomoo
Generate Biomedicines: Q2 Earnings Snapshot - marketscreener.com
Generate Biomedicines reports Q2 2026: $6.3M revenue, $67.3M net loss, $457.4M cash - TradingView
Generate Biomedicines, Inc. Q2 2026: Revenue $6.3M, EPS $(0.52) — 10-Q Summary - TradingView
GENB: Phase 3 clinical and AI-driven pipeline progress offset by rising R&D costs and net loss - TradingView
Generate Biomedicines (GENB) posts Q2 loss but holds $457.4M cash after IPO - Stock Titan
This Is Nvidia CEO Jensen Huang's Favorite Biotech Stock -- and You've Probably Never Heard of It - finance.yahoo.com
Generate Biomedicines, Inc. (GENB) Return On Assets (TTM) - Zacks Investment Research
Generate Biomedicines (GENB) Rallies 4.36% as Biotech Sentiment ShiftsMomentum Stock Picks - vinanet.vn
Generate Biomedicines, Inc. Revenue Breakdown – NASDAQ:GENB - TradingView
JPMorgan Small Cap Value Portfolio's Generate Biomedicines Inc(GENB) Holding History - GuruFocus
Generate Biomedicines, Inc. (GENB) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Generate Biomedicines: Post Mega-Money IPO, Caution Is Warranted (NASDAQ:GENB) - Seeking Alpha
If You Invested $1,000 in Generate Biomedicines (GENB) - Stock Titan
Price to cash flow ratio of Generate Biomedicines, Inc. – BX:GENB - TradingView
Generate Biomedicines (GENB) Surges 5.96% – Support and Resistance Levels in FocusVolatility Stop - dars.gov.et
Price to sales forward of Generate Biomedicines, Inc. – BX:GENB - TradingView
Generate Biomedicines Inc Azioni (GENB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):